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Abstract
OBJECTIVE: To study the therapeutic effect Bufei
granule, which is a traditional Chinese drug that
can enhance the immune function of the lung, on
patients with stable chronic obstructive pulmonary
disease (COPD).
METHODS: This is a randomized, double blinded,
placebo-controlled, and multicenter clinical study.
Three medical centers in Tianjin, China, participat-
ed in the trial. A total of 140 patients with stable
COPD were enrolled and randomized into two
groups, with 70 patients in each. The treatment
group was treated with Bufei granule, while the
control group received Bufei placebo. The pharma-
cological treatment lasted for 12 weeks from the
date of enrollment. Then, the indexes of patients
were observed. Data were analyzed to study the ef-
fect of Bufei granule, with the frequency of acute
exacerbation as the primary outcome. Traditional
Chinese Medicine syndromes, Modified British Med-
ical Research Council dyspnea scale score, St.
George's respiratory questionnaire scores, pulmo-
nary function, and serum inflammatory marker lev-
els [including interleukin-6 (IL-6), interleukin-8, tu-
mor necrosis factor-α, and transformation growth
factor-β1] were the secondary outcomes.
RESULTS: During the 12-week treatment, treat-
ment and control groups had no adverse reactions.
The analysis of the indexes obtained from all pa-
tients showed that the therapeutic effect in the
treatment group was significantly better than that
in the control group because most of the similar
probabilities of primary and secondary outcomes
were less than 0.05, except for the level of IL-6.
CONCLUSION: Bufei granule can treat patients
with stable COPD by lowering the frequency of
acute exacerbation, improving the quality of life,
and alleviating the severity of inflammation.
© 2014 JTCM. All rights reserved.
Key words: Bufei Granule; Pulmonary disease,
chronic obstructive; Stable stage; Randomized con-
trolled trial
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) af-
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flicts 10% of the global population over the age of 40
years1 and will be the third leading cause of mortality
by 2020.2 COPD is defined as a preventable and treat-
able respiratory disease characterized by partially revers-
ible chronic airflow obstruction. This obstruction is
progressive and characterized by inflammation of the
lungs in response to inhalation of noxious particles or
toxic gases, especially cigarette smoke.3 Although
COPD is a leading cause of global morbidity and mor-
tality, current therapeutic strategies have shown little
success in reliving inflammation and slowing progres-
sion. For example, β2-adrenergic agonists, which bene-
fit asthma by alleviating reversible airflow limitation,
have little effect on the irreversible obstruction ob-
served in COPD. Moreover, glucocorticosteroids, an-
other main treatment for COPD, was proven to be
largely insensitive to COPD-associated inflammation.4
Experts in Traditional Chinese Medicine (TCM) have
studied COPD for several decades. Many studies
found that traditional Chinese drugs did have positive
effects in treating patients with stable COPD.5-7 How-
ever, most studies lack reasonably designed research
schemes, all of which were either performed at only
one medical center or not placebo-controlled. In this
paper, we used Bufei granule, which is a traditional
Chinese drug that enhances the lung's immune func-
tion, to study the therapeutic effect of TCM in treat-
ing patients with stable COPD.
METHODS
Design
This is a randomized and double blinded, placebo-con-
trolled, and multicenter clinical study. The study was
conducted in three medical centers (The Second Affili-
ated Hospital of Tianjin University of TCM, Tianjin
Chest Hospital, and Tianjin Haihe Hospital), which
are all AAA hospitals in Tianjin, China. The study last-
ed from May 1st, 2008 to May 31st, 2011.
Ethics
The trial was approved by the Ethics Committee of
Tianjin University of TCM, and adhered to the princi-
ples of the Declaration of Helsinki. The protocol and
its informed consent form were judged by the Commit-
tee to be ethically and scientifically satisfactory to the
aims. Written informed consent was obtained from all
participants or their representatives before enrolling.
Participants
According to the inclusion and exclusion criteria, 140
stable COPD patients were enrolled (50 patients from
the Second Affiliated Hospital of Tianjin University of
TCM, 50 patients from Tianjin Chest Hospital, and
40 patients from Tianjin Haihe Hospital).
Inclusion criteria: (a) COPD patients who were diag-
nosed according to the diagnosis criteria in global strat-
egy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease reported by
Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD);8 (b) stable COPD patients, with the se-
verity of airflow limitation based on post-bronchodila-
tor forced expiratory volume in one second (FEV1)
from GOLD2 (moderate) to GOLD3 (severe). (Pulmo-
nary function test: FEV1/forced vital capacity (FVC)%<
70%, 30%≤FEV1/predicted value (%)≤80%, tested by
Pulmonary Function Testing System, Model: Master-
Screen PFT, Supplied by CareFusion-Jaeger);8 (c)
COPD patients who were diagnosed as "deficiency of
lung, spleen, and kidney accompanied with retention
of phlegm and blood stasis" in TCM;9 (d) aged 40-75
years; (e) completed and submitted the informed con-
sent form.
Exclusion criteria: (a) patients who suffered from other
primary pulmonary diseases such as bronchiectasis, tu-
berculosis, or idiopathic pulmonary fibrosis; (b) aller-
gic constitution or Chinese herb allergies; (c) pregnan-
cy, planning to be pregnant, or lactating; (d) severe he-
patic or renal deficiency; (e) severe primary diseases of
the heart, brain, digestive system, or hematopoietic sys-
tem; (f) mental diseases; (g) those who participated in
other clinical studies in the past three months; (h)
those who used other medicinal interventions regularly
to treat stable COPD in the past three months.
Medications
(a) Bufei granule [Produced by Pharmaceutical Centre
of the Second Affiliated Hospital of Tianjin University
of TCM, Tianjin, China; Production batch number:
200702003, composed of Dangshen (Radix Codonop-
sis), Shudihuang (Radix Rehmanniae Praeparata), Shan-
zhuyu (Fructus Corni), Mahuang (Herba Ephedra Sini-
ca), and Chenpi (Pericarpium Citri Reticulatae), 8 g/
bag]; (b) Bufei placebo (Produced by Pharmaceutical
Centre of the Second Affiliated Hospital of Tianjin
University of TCM, Tianjin, China; composed of 5%
crude drug of Bufei granule and 95% starch, 8 g/bag).
Randomization and blindness
Using the stratified block randomization method, ac-
cording to a predetermined proportion of 1∶1, the 140
stable COPD patients were randomized to the treat-
ment group or the control group, with 70 patients in
each group. Staffs not involved in this clinical study
were involved in the randomization process. After en-
rollment in the trial, the participants were given a fixed
prescription and received study medications from phar-
macy staff according to the enrollment sequence. Both
Bufei granule and Bufei placebo had the same appear-
ance, shape, color, and packaging, so the research phy-
sicians and participants were not able to know the dif-
ference.
Treatment
During the trial, patients in the treatment group were
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treated with Bufei granule (two bags per time, twice a
day), while those in the control group treated with Bu-
fei placebo (two bags per time, twice a day). All pa-
tients were guided by medicinal use and health educa-
tion such as exercise, diet, and abdominal breathing.
The pharmacological treatment lasted for 12 weeks
from the date of enrollment and during this time, all
patients were not permitted to receive other medicinal
interventions for their COPD.
Outcome measures
Data were captured on admission and on the day after
the completion of the therapy. A 12-month follow-up
was carried out to record the frequency of acute exacer-
bation at the end of the sixth and twelfth months. Dur-
ing the follow-up, patients could use other medicinal
interventions for stable COPD except for other TCM
medicines.
Efficacy criteria according to the reference9
Clinical control (Ⅰ): most of the clinical symptoms
disappeared and the TCM syndrome total score de-
creased no less than 95%; Significantly effective (Ⅱ):
most of the clinical symptoms disappeared and the
TCM syndrome total score decreased no less than
70%; Effective (Ⅲ): some of the clinical symptoms im-
proved and the TCM syndrome total score decreased
no less than 30%; Ineffective (Ⅳ): clinical symptoms
did not improve or even deteriorate and the TCM syn-
drome total score decreased less than 30%.
Primary outcome
Frequency of acute exacerbation: acute exacerbation of
COPD was diagnosed according to the diagnosis crite-
ria in global strategy for the diagnosis, management,
and prevention of chronic obstructive pulmonary dis-
ease reported by GOLD.8
Secondary outcomes
The total score on a TCM syndrome form: (a) the
TCM syndrome mainly included cough, expectora-
tion, and shortness of breath. The severity of each
symptom was divided into four degrees: none (score:
0), mild (score: 2), moderate (score: 4) and severe
(score: 6). The TCM syndrome form was filled out
and the scores of each symptom were summed. The
higher the total score, the more serious the symptoms;
(b) Modified British Medical Research Council
(mMRC) dyspnea scale score;10 (c) St. George's respira-
tory questionnaire (SGRQ) score;11 (d) Pulmonary
function [FEV1; FVC; FEV1/predicted value; FEV1/
FVC; Mean maximum expiratory flow (MMEF) 75/
25; Peak expiratory flow (PEF)]; (e) Serum inflamma-
tory marker levels, such as interleukin-6 (IL-6), inter-
leukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and
transformation growth factor-β1 (TGF-β1), using en-
zyme-linked immunosorbent assay (ELISA).
Indexes of safety
General medical examination; regular blood and urine
tests; electrocardiogram (ECG); liver function [glutam-
ic-pyruvic transaminase (GPT), glutamic-oxaloacetic
transaminase (GOT)]; renal function [blood urea nitro-
gen (BUN), creatinine]; and record of adverse events
(headache or fainting).
All the above indexes were examined before and after
the trial treatment.
Data management
Data input: database manager used was EpiData 3.1
(EpiData Association, Odense, Denmark). Data were
inputted by two full-time personnel independently.
Data verification: duplicate input results were com-
pared.
Statistical analysis and expression
Data underwent statistical analysis by a third party.
Ranked data were assessed by Ridit analysis. Quantita-
tive data were summarized as mean±standard deviation
( xˉ ±s). Paired t-test was used for before and after treat-
ment comparisons within the treatment and control
groups, while independent samples t-test was used be-
tween the two groups. Chi-squared test was applied for
comparing qualitative data. Non-parametric test was
used when data were not normally distributed. Statisti-
cal analysis was performed using SPSS 11.5 software
(International Business Machines Cooperation, Ar-
monk, New York, United States), and P<0.05 was con-
sidered statistically significant.
RESULTS
Comparison of baseline characteristics between the
two groups
All patients in the two groups were of Chinese Han
ethnicity. During the study period, 10 of the 140 pa-
tients were lost. Of the 10 lost, 1 (1.42% ) was from
the treatment group, and 9 were (12.86% ) from the
control group. All the data from these 10 participants
were excluded from the statistical analysis. There were
not significant differences (P>0.05) in the number of
cases, age, gender, severity, and disease course between
the two groups (Figure 1)
Comparison of the medical interventions during the
12-month follow-up between the two groups
During the 12-month follow-up, 23 out of 69 patients
in the treatment group were treated with long acting
beta agonists (LABA)/inhaled corticosteroid (ICS) (sal-
meterol xinafoate 50 μg/fluticasone propionate 250 μg,
twice a day). 20 patients were treated with theophyl-
line sustained release tablets (0.2 g one time, twice a
day). 26 patients did not receive regular treatment. In
the control group, 22, 18, and 21 patients received LA-
BA/ICS, theophylline sustained release tablets, and no
regular treatment, respectively. There were no signifi-
cant differences (P>0.05) between the two groups in
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medical interventions.
Comparison of clinical efficacy between the two
groups after treatment
The clinical efficacy in the treatment group was
60.87%, which was significantly higher than the value
of 18.03% in the control group (P<0.05) (Table 1).
Comparison of frequency of acute exacerbation
At the end of the sixth month, the frequency of acute
exacerbation of COPD showed no significant differ-
ence (P>0.05) between the two groups. However, the
treatment lowered the frequency of acute exacerbation
significantly (P<0.05) at the end of the twelfth month
(Table 2).
Comparison of TCM syndrome score
There was no significant difference (P>0.05) between
the two groups before treatment. The difference in the
total TCM syndrome score of the treatment group was
significant (P<0.05) before and after treatment, and
there was a significant difference (P<0.05) between the
two groups after treatment (Table 3).
Comparison of mMRC dyspnea scale scores
The differences in the mMRC dyspnea scale scores be-
tween the two groups were not significant (P>0.05) be-
fore treatment. Significant differences (P<0.05) were
observed in the treatment group from before to after
treatment, but there were no significant differences (P>
0.05) in the control group from before to after treat-
Group
Treatment
Control
n
69
61
Ⅰ
0
0
Ⅱ
6 (8.69)
1 (1.64)
Ⅲ
36 (52.17)
10 (16.39)
Ⅳ
27 (39.14)
50 (81.97)
Total effective
42 (60.87)a
11 (18.03)
Table 1 Comparison of clinical efficacy [n (%)]
Notes: treatment group were treated with Bufei granule (two bags per time, twice a day); control group were treated with Bufei placebo
(two bags per time, twice a day). Ⅰ: clinical control; Ⅱ: significantly effective; Ⅲ: effective; Ⅳ: ineffective. Compared with the control
group, aP<0.05.
Group
Treatment
Control
n
69
61
Frequency of exacerbation (6th month)
0.11±0.03a
0.13±0.05
Frequency of exacerbation (12th month)
0.28±0.09b
0.88±0.35
Table 2 Comparison of the frequency of acute exacerbation (times, xˉ ±s)
Notes: treatment group were treated with Bufei granule (two bags per time, twice a day); control group were treated with Bufei placebo
(two bags per time, twice a day). Compared with the control group, aP>0.05, bP<0.05.
Figure 1 Flow diagram of the trial
140 stable COPD patients were
randomly assigned by computer in
accordance with 1∶1.
Data were captured on
admission and on the day
after the completion of the
therapy. A 12-month
follow-up was carried out to
record the frequency of
acute exacerbation at the
end of the sixth and twelfth
months. 9 patients were lost
during the trial.
70 patients were assigned to
the treatment group which
was treated with Bufei
granule.
70 patients were assigned to
the control group which was
treated with Bufei placebo.
Data were captured on
admission and on the day
after the completion of the
therapy. A 12-month
follow-up was carried out
to record the frequency of
acute exacerbation at the
end of the sixth and twelfth
months. 1 patient was lost
during the trial.
69 patients were analyzed. 61 patients were analyzed.
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ment. After treatment, there were statistically signifi-
cant differences (P<0.05) between the two groups (Ta-
ble 4).
Comparison of SGRQ scores
Comparing the two groups before treatment, the differ-
ences in respiratory symptoms, activity limitation, and
the total score were not significant (P>0.05). However,
the difference in disease effect was significant (P<0.05).
The differences in respiratory symptoms, activity limi-
tation, disease affect, and total score in the two groups
were statistically significant (P<0.05) from before to af-
ter treatment. There were significant differences (P<
0.05) in respiratory symptoms, activity limitation, dis-
ease affect, and total score between the two groups af-
ter treatment (Table 5).
Comparison of pulmonary function
The differences in pulmonary function between the
two groups were not significant (P>0.05) before treat-
ment. There were not significant differences (P>0.05)
in the two groups from before to after treatment. After
treatment, significant differences (P<0.05) were ob-
served in FEV1, FVC, FEV1/predicted value, FEV1/
FVC, and PEF between the two groups (Table 6).
Comparisons of serum inflammatory markers
The differences in the serum levels of IL-6, IL-8,
TNF-α, and TGF-β1 between the two groups were
not significant (P>0.05) before treatment. The serum
levels of IL-6, IL-8, TNF-α, and TGF-β1 in the treat-
ment group decreased significantly (P<0.05) after treat-
ment. There were no significant differences (P>0.05)
in the levels of IL-6, IL-8, TNF-α, and TGF-β1 in the
Group
Treatment
Control
n
69
61
The total score of TCM syndrome form
Before treatment
12.0±4.2a
13.0±4.7
After treatment
7.1±2.6bc
10.9±2.8
Table 3 Comparison of the total TCM syndrome score (scores, xˉ ±s)
Notes: treatment group were treated with Bufei granule (two bags per time, twice a day); control group were treated with Bufei placebo
(two bags per time, twice a day). TCM: Traditional Chinese Medicine. Compared with the control group, aP>0.05, bP<0.05; compared
within the same group before treatment, cP<0.05.
Group
Treatment
Control
n
69
61
Degree distribution before treatment
0
3
2
1
24
28
2
32
23
3
10
8
4
0
0
Degree distribution after treatment
0
8
2
1
41
25
2
17
29
3
3
5
4
0
0
Table 4 Comparison of mMRC dyspnea scale scores (cases)
Notes: treatment group were treated with Bufei granule (two bags per time, twice a day); control group were treated with Bufei placebo
(two bags per time, twice a day). mMRC: Modified British Medical Research Council.
Group
Treatment
Control
n
69
61
Before treatment
After treatment
Before treatment
After treatment
Respiratory symptoms
45±20
30±12ab
50±23
42±20b
Activity limitation
50±19
36±9ab
55±21
47±17b
Disease affect
32±18
19±7ab
40±18
34±11b
Total score
41±17
26±8ab
46±17
38±12b
Notes: treatment group were treated with Bufei granule (two bags per time, twice a day); control group were treated with Bufei placebo
(two bags per time, twice a day). SGRQ: St. George's respiratory questionnaire. Compared with the control group, aP<0.05; compared
within the same group before treatment, bP<0.05.
Table 5 Comparison of SGRQ scores (scores, xˉ ±s)
Groups
Treatment
Control
n
69
61
Before treatment
After treatment
Before treatment
After treatment
FEV1 (L)
1.3±0.6
1.4±0.6a
1.2±0.4
1.0±0.5
FVC (L)
2.2±0.8
2.3±0.9a
2.1±0.7
1.9±0.7
FEV1 (%)
45.7±17.1
51.0±12.3a
46.1±14.7
41.8±15.8
FEV1/FVC (%)
56.0±10.2
62.5±20.8a
56.9±10.0
51.9±7.4
MMEF75/25 (%)
18.5±11.0
20.8±12.3
20.0±13.2
19.5±11.9
PEF (L/min)
45.9±19.0
45.4±21.6a
40.2±16.8
36.9±15.6
Table 6 Comparison of pulmonary function ( xˉ ±s)
Notes: treatment group were treated with Bufei granule (two bags per time, twice a day); control group were treated with Bufei placebo
(two bags per time, twice a day). FEV1: forced expiratory volume in one second; FVC: forced vital capacity; MMEF: mean maximum
expiratory flow; PEF: peak expiratory flow. Compared with the control group, aP<0.05.
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control group from before to after treatment (Table 7).
Adverse reactions
There were no adverse reactions observed in either
group during the trial treatment period.
DISCUSSION
In this study, a total of 140 stable COPD patients (10
were lost to follow up) from three medical centers were
treated for 12 weeks and followed up for 12 months.
Table 3 shows that the frequency of acute exacerbation
at the end of the twelfth month in the treatment group
was around one third of that in the control group,
while there was no significant difference between the
two groups at the end of the sixth month. This indi-
cates that patients might get more long-term benefit
from Bufei granule intervention. Additionally, clinical
efficacy in the treatment group was higher than that in
the control group as shown in Table 2. However, the
other three indicators shown in Tables 4-6, namely the
TCM syndrome total score, the mMRC dyspnea scale
score, respiratory symptoms score in SGRQ in the
treatment group were significantly lower than those in
the control group. This means that Bufei granule can
effectively relieve the symptoms of stable COPD pa-
tients such as cough, expectoration, and dyspnea. Addi-
tionally, exercise tolerance and health status can be im-
proved as the SGRQ activity limitation, disease effect,
and total scores were lower in the treatment group
than in the control group.
Moreover, Bufei granule might protect pulmonary
function from deteriorating as FEV1, FVC, FEV1/pre-
dicted value, FEV1/FVC, and PEF of the patients were
higher in the treatment group. Therefore, we can con-
clude that Bufei granule is effective in treating stable
COPD patients because all of the effects of Bufei gran-
ule are consistent with the treatment goals recommend-
ed by GOLD, i.e. reducing both current symptoms
and future risks.12
The effect of Bufei granule on inflammation of lungs
and its mechanism was also studied, since chronic air-
way inflammation is a key pathogenesis in the process
of COPD13 and there is evidence of systemic inflamma-
tion in patients with COPD.14,15 CD8+ T lymphocytes,
neutrophils, alveolar macrophages, and bronchial epi-
thelial cells play an important role in the inflammation
during COPD by releasing multiple cytokines after be-
ing activated. Our other study, which focused on the
comparison of serum levels of inflammatory markers
among stable COPD patients and healthy adults,
found that the serum levels of TNF-α, IL-8, IL-6, and
TGF-β1 in COPD patients were much greater.
Generally, Bufei granule can alleviate the severity of in-
flammation by regulating the serum levels of TNF-α,
IL-8, IL-6, and TGF-β1. In this study, it was found
that Bufei granule significantly lowered the serum level
of TNF-α, the expression of which in COPD patients
was elevated, owing to either induction by cigarette
smoke or genetic aberrations,16,17 as shown in Table 8.
Therefore, we believed that it could decrease the re-
lease of several inflammatory mediators such as IL-8,
by partly inhibiting the activation of TNF-α recep-
tor.18-20 Additionally, lowering the level of TNF-α
might reduce airway mucous cells metaplasia and hy-
persecretion21 and emphysematous lesions, and be con-
ducive to the prevention of the progression of COPD
and disability. This is because circulating TNF-α levels
are inversely correlated with the partial pressure of oxy-
gen and increased dyspnea severity.22,23 Nevertheless,
Bufei granule may increase the exercise tolerance and
ameliorate activity limitation because of lower serum
level of TNF-α that is involved systematically in in-
flammatory skeletal muscles' dysfunction and osteopo-
rosis. Thus, we concluded that lowering the serum lev-
el of TNF-α is a crucial effect of Bufei granule that im-
proves the quality of life and alleviates inflammation se-
verity.
In our study, there was no significant difference in the
serum levels of IL-6 in the treatment group, before and
after treatment, as shown in Table 8. On the one
hand, the maintenance of IL-6 levels might enhance
pulmonary immune function, because IL-6 can up-reg-
ulate the local immune response, induce the release of
systemic acute phase reactant, and inhibit TNF-α re-
lease of macrophage. This then reduces the inflamma-
tory response involved in airway inflammation and air-
way remodeling in COPD. On the other hand, it was
shown that the level of IL-6 in the sputum of COPD
patients increased, and the increase was positively corre-
Parameter
IL-6
IL-8
TNF-α
TGF-β1
Treatment group (n=69)
Before treatment
4.16±2.47
5.49±2.26
2.89±1.24
1900.39±934.95
After treatment
3.54±0.65
2.01±0.45a
1.28±0.23a
891.43±134.24a
Control group (n=61)
Before treatment
3.84±1.74
6.36±2.45
2.61±0.80
1727.42±363.88
After treatment
3.62±0.67
5.43±1.89
2.58±0.65
1661.67±234.69
Table 7 Comparison of serum inflammatory markers (pg/mL, xˉ ±s)
Notes: treatment group were treated with Bufei granule (two bags per time, twice a day); control group were treated with Bufei placebo
(two bags per time, twice a day). IL-6: interleukin-6; IL-8: interleukin-8; TNF-α: tumor necrosis factor-α; TGF-β1: transformation
growth factor-β1. Compared within the same group before treatment, aP<0.05.
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lated with the level of pulmonary function.24 There-
fore, we can conclude that the effects of mitigating in-
flammation and improving pulmonary function of Bu-
fei granule are related to the regulation of the IL-6 level.
Our study also showed a significant decrease of the se-
rum level of IL-8 after the intervention with Bufei
granule, as shown in Table 8. IL-8 causes migration of
inflammatory cells to the location of inflammation, es-
pecially in neutrophils, providing a binding capacity
for neutrophils to the inflammatory spots,25 and also
amplifies the effect of airway inflammation.26 Conse-
quently, it is reasonable to believe that the effect of low-
ering IL-8 levels in Bufei granule plays an important
role in reducing the inflammation of stable COPD.
Another finding in our study is that Bufei granule sig-
nificantly decreased the serum level of TGF-β1, which
is effective in anti-inflammation and is a potent induc-
tor of airway fibrosis and extracellular deposition of col-
lagen.27 In COPD patients, increased expression of
TGF-β1 in the airway epithelium is associated with en-
hanced fibrotic airway remodeling.28 In addition to
TGF-β1 overproduction, the altered TGF-β1 signal-
ing and several TGF-β1 polymorphisms have been pos-
tulated to play a role in the pathogenesis of COPD
and emphysema.29,30 Thus, Bufei granule's effect of low-
ering the level of TGF-β1 benefits stable COPD pa-
tients by reducing the inflammation and lessening the
airway remodeling.
In TCM, COPD is similar to the diseases "lung-disten-
tion," "dyspnea syndrome," "phlegm retention," and
"internal injury cough." From the perspective of TCM
theory, COPD mainly affects the lung in the early
stage of pathophysiology, and along with the progres-
sion of the disease, eventually leads to Ben-root defi-
ciency Biao-branch excess syndrome characterized by
Qi deficiency of the lung, spleen, and kidney accompa-
nied with phlegm retention and blood stasis. The
pathogenesis of COPD is deficiency of anti-pathogenic
Qi and excess of pathogenic Qi. Therefore, the treat-
ment principle of strengthening vital Qi combined
with dispelling blood stasis and resolving phlegm is
used. Bufei granule is formulated based on this treat-
ment principle, so it can enhance the immune func-
tion of the lung and improve the function of the Zang-
Fu organs to protect stable COPD patients from pro-
gression of the disease.
To the best of our knowledge, this is the first random-
ized and double blind, placebo-controlled, and multi-
center clinical study of TCM-based intervention on sta-
ble COPD. Our study confirms that Bufei granule ef-
fectively treats stable COPD patients by lowering the
frequency of acute exacerbation, improving quality of
life, and alleviating the severity of inflammation.
Because of financial constraints, the sample of patients
in the study was relatively small and the follow-up was
not long enough. Furthermore, we did not observe all
the outcome measures during the follow-up to investi-
gate the long-term effect and safety of Bufei granule.
We plan to explain in future the clinical efficacy mech-
anism of Bufei granule in vivo and in vitro studies. Nev-
ertheless, Bufei granule has shown good efficacy with-
out significant side effects during a 12-week treatment.
Bufei granule could be a new option in the treatment
of stable COPD.
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